Stockreport

FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio (NasdaqGS:IBRX) has had its resubmitted supplemental Biologics License Application for ANKTIVA plus BCG in papillary non muscle invasive bladder cancer form [Read more]